These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 18573136)

  • 1. Beyond anemia: the clinical impact of the physiologic effects of erythropoietin.
    Diskin CJ; Stokes TJ; Dansby LM; Radcliff L; Carter TB
    Semin Dial; 2008; 21(5):447-54. PubMed ID: 18573136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The clinical impact of the physiological effects of erythropoietin and erythropoietin-stimulating agents on the incidence of malignancy, and hypertension: beyond anaemia].
    Ortega LM; Contreras G
    Nefrologia; 2009; 29(4):288-94. PubMed ID: 19668298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Erythropoietin: indications and measurement].
    Klein E; Georges A; Brossaud J; Bosredon Kd; Bordenave L; Corcuff JB
    Ann Biol Clin (Paris); 2009; 67(5):505-15. PubMed ID: 19789122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonhematologic complications of erythropoietin therapy.
    Zhu X; Perazella MA
    Semin Dial; 2006; 19(4):279-84. PubMed ID: 16893404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anemia as a risk factor and therapeutic target in heart failure.
    Felker GM; Adams KF; Gattis WA; O'Connor CM
    J Am Coll Cardiol; 2004 Sep; 44(5):959-66. PubMed ID: 15337204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erythropoietin in clinical practice: current use, effect on survival, and future directions.
    Oster HS; Hoffman M; Prutchi-Sagiv S; Katz O; Neumann D; Mittelman M
    Isr Med Assoc J; 2006 Oct; 8(10):703-6. PubMed ID: 17125118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of route of EPO administration on hemodialysis arteriovenous vascular access failure: a randomized controlled trial.
    Lee YK; Koo JR; Kim JK; Park II; Joo MH; Yoon JW; Noh JW; Vaziri ND
    Am J Kidney Dis; 2009 May; 53(5):815-22. PubMed ID: 19324483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An unusual etiology of erythropoietin resistance: hyperthyroidism.
    Kaynar K; Ozkan G; Erem C; Gul S; Yilmaz M; Sonmez B; Ozdemir F; Ulusoy S
    Ren Fail; 2007; 29(6):759-61. PubMed ID: 17763175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erythropoietin is a multifunctional tissue-protective cytokine.
    Erbayraktar S; Yilmaz O; Gökmen N; Brines M
    Curr Hematol Rep; 2003 Nov; 2(6):465-70. PubMed ID: 14561390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erythropoietin: physiology and clinical experience.
    Varet B; Casadevall N; Lacombe C; Nayeaux P
    Semin Hematol; 1990 Jul; 27(3 Suppl 3):25-31. PubMed ID: 2198661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erythropoietin-induced hypertension.
    Ismail N; Ikizler TA
    J Med Liban; 1997; 45(1):25-30. PubMed ID: 9421942
    [No Abstract]   [Full Text] [Related]  

  • 12. Erythropoietin resistance in the treatment of the anemia of chronic renal failure.
    Priyadarshi A; Shapiro JI
    Semin Dial; 2006; 19(4):273-8. PubMed ID: 16893403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular protection by erythropoietin: new therapeutic implications?
    Joyeux-Faure M
    J Pharmacol Exp Ther; 2007 Dec; 323(3):759-62. PubMed ID: 17717190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anemia in chronic heart failure: etiology and treatment options.
    Westenbrink BD; de Boer RA; Voors AA; van Gilst WH; van Veldhuisen DJ
    Curr Opin Cardiol; 2008 Mar; 23(2):141-7. PubMed ID: 18303527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The cardiorenal syndrome and erythropoietin].
    Kes P; Basić-Jukić N; Jurić I; Basić-Kes V
    Acta Med Croatica; 2008; 62 Suppl 1():21-31. PubMed ID: 18578329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Erythropoietin--complications, side effects].
    Koide K; Arai T
    Nihon Rinsho; 1991 Dec; 49 Suppl():679-87. PubMed ID: 1808335
    [No Abstract]   [Full Text] [Related]  

  • 17. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis.
    Nakamoto H; Mimura T; Honda N
    Hemodial Int; 2008 Oct; 12 Suppl 2():S9-S14. PubMed ID: 18837771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DMT1 (NRAMP2/DCT1) genetic variability and resistance to recombinant human erythropoietin therapy in chronic kidney disease patients under haemodialysis.
    Costa E; Rocha S; Rocha-Pereira P; Reis F; Castro E; Teixeira F; Miranda V; do Sameiro Faria M; Loureiro A; Quintanilha A; Belo L; Santos-Silva A
    Acta Haematol; 2008; 120(1):11-3. PubMed ID: 18667808
    [No Abstract]   [Full Text] [Related]  

  • 19. High-dose folic acid supplements and responsiveness to rHu-EPO in HD patients.
    Sepe V; Adamo G; Giuliano MG; Soccio G; Libetta C; Dal Canton A
    Nephrol Dial Transplant; 2006 Jul; 21(7):2036. PubMed ID: 16504977
    [No Abstract]   [Full Text] [Related]  

  • 20. The EPO/iron marriage: counseling needed.
    Bralow S
    Nephrol News Issues; 2007 Jun; 21(7):53, 55. PubMed ID: 17623987
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.